Inhibition of cardiac hypertrophy by probiotic-fermented purple sweet potato yogurt in spontaneously hypertensive rat hearts

Lin,Pei-Pei; Hsieh,You-Miin; Kuo,Wei-Wen; Lin,Chien-Chung; Tsai,Fuu-Jen; Tsai,Chang-Hai; Huang,Chih-Yang; Tsai,Cheng-Chih

doi:10.3892/ijmm.2012.1154

Inhibition of cardiac hypertrophy by probiotic-fermented purple sweet potato yogurt in spontaneously hypertensive rat hearts

Authors:
- Pei-Pei Lin
- You-Miin Hsieh
- Wei-Wen Kuo
- Chien-Chung Lin
- Fuu-Jen Tsai
- Chang-Hai Tsai
- Chih-Yang Huang
- Cheng-Chih Tsai
View Affiliations

Affiliations: Department of Food and Nutrition, Providence University, Taichung, Taiwan, R.O.C., Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C., Orthopaedic Department, Armed Forces General Hospital, Taichung, Taiwan, R.O.C., Graduate Institute of Chinese Medical Science, Taichung, Taiwan, R.O.C., Department of Healthcare Administration, Asia University, Taichung, Taiwan, R.O.C., Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, R.O.C., Department of Food Science and Technology, HungKuang University, Taichung, Taiwan, R.O.C.
Published online on: October 12, 2012 https://doi.org/10.3892/ijmm.2012.1154
Pages: 1365-1375

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiovascular hypertrophy is a common feature of hypertension and an important risk factor for heart damage. The regression of cardiovascular hypertrophy is currently considered an important therapeutic target in reducing the omplications of hypertension. The aim of this study was to investigate the inhibition of cardiac hypertrophy by probiotic-fermented purple sweet potato yogurt (PSPY) with high γ-aminobutyric acid (GABA) content in spontaneously hypertensive rat (SHR) hearts. Six-week-old male SHRs were separated randomly and equally into 4 experimental groups: sterile water, captopril and 2 PSPY groups with different doses (10 and 100%) for 8 weeks. The changes in myocardial architecture and key molecules of the hypertrophy-related pathway in the excised left ventricle from these rats were determined by histopathological analysis, hematoxylin and eosin staining and western blot analysis. Abnormal myocardial architecture and enlarged interstitial spaces observed in the SHRs were significantly decreased in the captopril and PSPY groups compared with the sterile water group. Moreover, the increases in atrial natriuretic peptide, B-type natriuretic peptide, phosphorilated protein kinase Cα and calmodulin-dependent protein kinase II levels in the left ventricle were accompanied by hypertension and increases in phosphorylated extracellular signal-regulated kinase 5 activities with enhanced cardiac hypertrophy. However, the protein levels of the hypertrophic-related pathways were completely reversed by the administration of PSPY. PSPY may repress the activation of ANP and BNP which subsequently inhibit the dephosphorylation of the nuclear factor of activated T-cells, cytoplasmic 3 and ultimately prevent the progression of cardiac hypertrophy.

View Figures

View References

1.	WW KuoCY ChuCH WuJA LinJY LiuYH HsiehKC UengSD LeeDJ HsiehHH HsuImpaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive ratsCell Biochem Funct23325331200510.1002/cbf.124415996002
2.	JA TowbinNE BowlesThe failing heartNature415227233200210.1038/415227a11805847
3.	D DebloisBS TeaD BeaudryP HametRegulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damageCan J Physiol Pharmacol832941200510.1139/y05-00115759048
4.	SE KjeldsenB DahlofRB DevereuxS JuliusP AurupJ EdelmanEffects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudyJAMA28814911498200210.1001/jama.288.12.1491
5.	CY HuangLY HaoDE BuetowInsulin-like growth factor-induced hypertrophy of cultured adult rat cardiomyocytes is L-type calcium-channel-dependentMol Cell Biochem2315159200210.1023/A:101443292322011952165
6.	SD LeeCH ChuEJ HuangMC LuJY LiuCJ LiuHH HsuJA LinWW KuoCY HuangRoles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligationAm J Physiol Endocrinol Metab291E306E314200610.1152/ajpendo.00127.200516825605
7.	JD MolkentinJR LuCL AntosA calcineurin-dependent transcriptional pathway for cardiac hypertrophyCell93215228199810.1016/S0092-8674(00)81573-19568714
8.	B WilkinsLJ De WindtOF BuenoJC BrazBJ GlascockTF KimballJD MolkentinTargeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophy growthMol Cell Biol2276037613200210.1128/MCB.22.21.7603-7613.200212370307
9.	N KomatsuzakiT NakamuraT KimuraJ ShimaCharacterization of glutamate decarboxylase from a high gamma-aminobutyric acid (GABA)-producer, Lactobacillus paracaseiBiosci Biotechnol Biochem72278285200810.1271/bbb.7016318256502
10.	H LiY CaoLactic acid bacterial cell factories for gamma-aminobutyric acidAmino Acids3911071116201010.1007/s00726-010-0582-720364279
11.	Y UenoK HayakawaS TakahashiK OdaPurification and characterization of glutamate decarboxylase from Lactobacillus brevis IFO 12005Biosci Biotechnol Biochem6111681171199710.1271/bbb.61.11689255981
12.	JY KimMY LeeGE JiYS LeeKT HwangProduction of gamma-aminobutyric acid in black raspberry juice during fermentation by Lactobacillus brevis GABA100Int J Food Microbiol1301216200910.1016/j.ijfoodmicro.2008.12.02819167126
13.	LA DennerJY WuTwo forms of rat brain glutamic acid decarboxylase differ in their dependence on free pyridoxal phosphateJ Neurochem44957965198510.1111/j.1471-4159.1985.tb12910.x3882886
14.	SH OhWG ChoiIT LeeSJ YunCloning and characterization of a rice cDNA encoding glutamate decarboxylaseJ Biochem Mol Biol38595601200510.5483/BMBRep.2005.38.5.59516202241
15.	S YokoyamaJ HiramatsuK HayakawaProduction of gamma-aminobutyric acid from alcohol distillery lees by Lactobacillus brevis IFO-12005J Biosci Bioeng939597200210.1016/S1389-1723(02)80061-516233172
16.	K HayakawaM KimuraK KasahaK MatsumotoH SansawaY YamoriEffect of a gamma-aminobutyric acid-enriched dairy product on the blood pressure of spontaneously hypertensive and normotensive Wistar-Kyoto ratsBr J Nutr92411417200410.1079/BJN2004122115469644
17.	K InoueT ShiraiH OchiaiM KasaoK HayakawaM KimuraH SansawaBlood-pressure-lowering effect of a novel fermented milk containing gamma-aminobutyric acid (GABA) in mild hypertensivesEur J Clin Nutr57490495200310.1038/sj.ejcn.160155512627188
18.	J YamakoshiS FukudaT SatohR TsujiM SaitoA ObataA MatsuyamaM KikuchiT KawasakiAntihypertensive and natriuretic effects of less-sodium soy sauce containing gamma-aminobutyric acid in spontaneously hypertensive ratsBiosci Biotechnol Biochem71165173200710.1271/bbb.6042417213662
19.	M PhilpottCC LimLR FergusonDietary protection against free radicals: A case for multiple testing to establish structure-activity relationships for antioxidant potential of anthocyanic plant speciesInt J Mol Sci101081103200910.3390/ijms10031081
20.	M PhilpottKS GouldC LimLR FergusonIn situ and in vitro antioxidant activity of sweetpotato anthocyaninsJ Agric Food Chem5215111513200410.1021/jf034593j15030203
21.	I Konczak-IslamM YoshimotoDX HouN TeraharaO YamakawaPotential chemopreventive properties of anthocyanin-rich aqueous extracts from in vitro produced tissue of sweet potato (Ipomoea batatas L.)J Agr Food Chem5159165922200310.1021/jf030066o13129295
22.	S de Pascual-TeresaDA MorenoC García-VigueraFlavanols and anthocyanins in cardiovascular health: A review of current evidenceInt J Mol Sci1116791703201020480037
23.	K NakamuraK FushimiH KouchiK MiharaM MiyazakiT OheM NambaInhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin IICirculation98794799199810.1161/01.CIR.98.8.7949727550
24.	HL LiAB WangY HuangDP LiuG LiuCN ZhangC WeiYQ LiuRT HuiCC LiangIsorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathwaysFree Radic Biol Med38243257200510.1016/j.freeradbiomed.2004.10.02015607907
25.	HL LiY HuangCN ZhangG LiuYS WeiAB WangYQ LiuRT HuiC WeiGM WilliamsEpigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathwaysFree Radic Biol Med4017561775200610.1016/j.freeradbiomed.2006.01.005
26.	TY WuCC TsaiYT HwangTH ChiuEffect of antioxidant activity and functional properties of Chingshey purple sweet potato fermented milk by Lactobacillus acidophilus, L. delbrueckii subsp lactis, and L gasseri strainsJ Food Sci77M2M8201210.1111/j.1750-3841.2011.02507.x22182227
27.	AM DeschampsFG SpinalePathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulationCardiovasc Res69666676200610.1016/j.cardiores.2005.10.00416426590
28.	PM KangS IzumoApoptosis in heart: basic mechanisms and implications in cardiovascular diseasesTrends Mol Med9177182200310.1016/S1471-4914(03)00025-X12727144
29.	J HeinekeJD MolkentinRegulation of cardiac hypertrophy by intracellular signalling pathwaysNat Rev Mol Cell Biol7589600200610.1038/nrm198316936699
30.	CF LiuYT TungCL WuBH LeeWH HsuTM PanAntihypertensive effects of Lactobacillus-fermented milk orally administered to spontaneously hypertensive ratsJ Agric Food Chem59453745432011
31.	T NishikimiN MaedaH MatsuokaThe role of natriuretic peptides in cardioprotectionCardiovasc Res69318328200610.1016/j.cardiores.2005.10.00116289003
32.	CH ChuBS TzangLM ChenCH KuoYC ChengLY ChenFJ TsaiCH TsaiWW KuoCY HuangIGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Gαq interaction and protein kinase C-α/CaMKII activation in H9c2 cardiomyoblast cellsJ Endocrinol197381390200818434368
33.	CY HuangLY HaoDE BuetowHypertrophy of cultured adult rat ventricular cardiomyocytes induced by antibodies against the insulin-like growth factor (IGF)-I or the IGF-I receptor is IGF-II-dependentMol Cell Biochem2336572200210.1023/A:101551432432812083381
34.	H OkamuraJ AramburuC Garcia-RodriguezConcerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activityMol Cell6539550200010.1016/S1097-2765(00)00053-8
35.	HW LimJD MolkentinCalcineurin and human heart failureNat Med5246247199910.1038/6430
36.	T KandaT TakahashiInterleukin-6 and cardiovascular diseasesJpn Heart J45183193200410.1536/jhj.45.183
37.	GC MeléndezJL McLartySP LevickY DuJS JanickiGL BrowerInterleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in ratsHypertension56225231201020606113
38.	T HiranoInterleukin 6 and its receptor: ten years laterInt Rev Immunol1624928419989505191
39.	H HirotaK YoshidaT KishimotoT TagaContinuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in miceProc Natl Acad Sci USA9248624866199510.1073/pnas.92.11.48627539136
40.	RL NicolN FreyG PearsonM CobbJ RichardsonEN OlsonActivated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophyEMBO J2027572767200110.1093/emboj/20.11.275711387209
41.	SJ CameronS ItohCP BainesC ZhangS OhtaW CheM GlassmanJD LeeC YanJ YangJ AbeActivation of big MAP kinase 1 (BMK1/ERK5) inhibits cardiac injury after myocardial ischemia and reperfusionFEBS Lett566255260200410.1016/j.febslet.2004.03.12015147905
42.	M KimuraK HayakawaH SansawaInvolvement of γ-aminobutyric acid (GABA) B receptors in the hypotensive effect of systemically administered GABA in spontaneously hypertensive ratsJpn J Pharmacol893883942002
43.	MY LinCL YenAntioxidative ability of lactic acid bacteriaJ Agric Food Chem4714601466199910.1021/jf981149l10563999